Minimally Invasive Neurological Therapy (MINT) represents a groundbreaking approach to treating neurological disorders with minimal tissue disruption. Diverging from traditional surgical methods that necessitate sizable incisions and extensive tissue manipulation, MINT utilizes advanced techniques to access and treat neurological conditions through small incisions or natural body openings. The primary objective is to achieve therapeutic outcomes comparable to conventional surgery while minimizing trauma, postoperative pain, and recovery time. MINT is particularly advantageous for patients with various neurological conditions, including brain tumors, epilepsy, and chronic pain syndromes. Employing specialized tools such as endoscopes and microscopes, surgeons can visualize and access targeted areas of the brain or spinal cord with precision, preserving healthy tissue and reducing damage to critical structures. One notable example of MINT is endoscopic transsphenoidal surgery, which allows surgeons to remove pituitary tumors through the nasal passages without the need for a craniotomy. Another example is endovascular therapy, wherein neurointerventionalists treat neurological conditions through blood vessels using catheters and imaging technology. These minimally invasive techniques offer patients safer, more effective treatment options with faster recovery times. As technology advances, the scope and applicability of MINT in neurology are expected to expand, further enhancing outcomes for patients with neurological disorders.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States